Literature DB >> 20887597

Expression profile of lipid metabolism-associated genes in hepatitis C virus-infected human liver.

Tatsuya Fujino1, Makoto Nakamuta, Ryoko Yada, Yoko Aoyagi, Kenichiro Yasutake, Motoyuki Kohjima, Kunitaka Fukuizumi, Tsuyoshi Yoshimoto, Naohiko Harada, Masayoshi Yada, Masaki Kato, Kazuhiro Kotoh, Akinobu Taketomi, Yoshihiko Maehara, Manabu Nakashima, Munechika Enjoji.   

Abstract

AIM: Recent studies have shown that lipid metabolic pathways are required for the entry, replication and secretion of hepatitis C virus (HCV). Although little is known about the life cycle of HCV in humans, the activation of cholesterol and fatty acid biosynthesis may be critical for HCV proliferation.
METHODS: We assessed the transcription levels of genes essential for cholesterol and fatty acid biosynthesis in liver samples obtained from patients with chronic hepatitis C and determined their correlations. The serum levels of low-density lipoprotein (LDL) cholesterol and HCV core antigen were also measured.
RESULTS: The gene expression of the LDL receptor (LDLR) was suppressed, whereas that of SREBP1c, liver X receptor-α (LXRα), fatty acid synthase (FASN), and HMG-CoA reductase and synthase (HMGR and HMGS) was significantly increased, and SREBP2 transcription was comparable in HCV-infected liver compared with normal liver. Positive correlations were found for LDLR versus HMGR, HMGR versus SREBP1c, and LDLR versus SREBP2 in the HCV-infected and control liver. Although the LXRα-SREBP1c-FASN pathway was upregulated, proteasome activator 28γ (PA28γ) was downregulated at the transcriptional level in HCV-infected liver, and was not significantly correlated with the other genes examined. The serum LDL cholesterol level was negatively correlated with LDLR and HMGR expression.
CONCLUSION: These results suggest that, in HCV-infected liver, the cholesterol load increases and cholesterol uptake is controlled, while de novo cholesterol synthesis is upregulated compared with the normal physiological state. The positive correlations in the expression levels of some cholesterol metabolism-associated genes indicate that not all of the metabolic pathways are dysregulated in HCV-infected liver.

Entities:  

Year:  2010        PMID: 20887597     DOI: 10.1111/j.1872-034X.2010.00700.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  24 in total

Review 1.  Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies.

Authors:  José A Del Campo; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Role of metabolism during viral infections, and crosstalk with the innate immune system.

Authors:  Juan José González Plaza; Nataša Hulak; Galina Kausova; Zhaxybay Zhumadilov; Ainur Akilzhanova
Journal:  Intractable Rare Dis Res       Date:  2016-05

3.  The strange and critical intersection of hepatitis C and lipoprotein metabolism: "C-zing" the oil.

Authors:  Stephen Caldwell; Kyle L Hoehn; Young S Hahn
Journal:  Hepatology       Date:  2012-12-12       Impact factor: 17.425

4.  Molecular cloning and characterization of NPC1L1 in the Chinese tree shrew (Tupaia belangeri chinensis).

Authors:  Xiuying Kui; Dandan Qiu; Wenguang Wang; Na Li; Pinfen Tong; Xiaomei Sun; Liangzi Jin; Wei Deng; Jiejie Dai; Caixia Lu
Journal:  Mol Biol Rep       Date:  2021-10-30       Impact factor: 2.316

5.  MicroRNA-185-5p mediates regulation of SREBP2 expression by hepatitis C virus core protein.

Authors:  Min Li; Qi Wang; Shun-Ai Liu; Jin-Qian Zhang; Wei Ju; Min Quan; Sheng-Hu Feng; Jin-Ling Dong; Ping Gao; Jun Cheng
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 6.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

7.  Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

Authors:  Eric G Meissner; Yu-Jin Lee; Anu Osinusi; Zayani Sims; Jing Qin; Dan Sturdevant; John McHutchison; Mani Subramanian; Maureen Sampson; Susanna Naggie; Keyur Patel; Alan T Remaley; Henry Masur; Shyam Kottilil
Journal:  Hepatology       Date:  2015-01-28       Impact factor: 17.425

8.  Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.

Authors:  Adeel A Butt; Triin Umbleja; Janet W Andersen; Kenneth E Sherman; Raymond T Chung
Journal:  Clin Infect Dis       Date:  2012-05-04       Impact factor: 9.079

9.  Hepatitis C Virus-Induced Degradation of Cell Death-Inducing DFFA-Like Effector B Leads to Hepatic Lipid Dysregulation.

Authors:  Emily M Lee; Ali Alsagheir; Xianfang Wu; Christy Hammack; John McLauchlan; Noriyuki Watanabe; Takaji Wakita; Norman M Kneteman; Donna N Douglas; Hengli Tang
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

10.  Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthase.

Authors:  Jing-Tang Huang; Ching-Ping Tseng; Mei-Huei Liao; Shao-Chun Lu; Wei-Zhou Yeh; Naoya Sakamoto; Chuan-Mu Chen; Ju-Chien Cheng
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.